Advisor Group Holdings, Inc. Satsuma Pharmaceuticals, Inc. Transaction History

Advisor Group Holdings, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.7 - $1.07 $11,200 - $17,120	16,000 New	16,000 $11,000
Q2 2022 Aug 10, 2022	BUY	$2.59 - $4.3 $2,590 - $4,300	1,000 New	1,000 $4,000
Q2 2020 Aug 14, 2020	SELL	$16.01 - $34.69 $94,859 - $205,538	-5,925 Closed	0 $0
Q1 2020 May 18, 2020	BUY	$14.53 - $30.69 $86,090 - $181,838	5,925 New	5,925 $128,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.